Last reviewed · How we verify
FOLFIRI-HD (folfiri-hd)
At a glance
| Generic name | folfiri-hd |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2, PHASE3)
- High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFIRI-HD CI brief — competitive landscape report
- FOLFIRI-HD updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI